Tags

Type your tag names separated by a space and hit enter

Selenium as an element in the treatment of ovarian cancer in women receiving chemotherapy.
Gynecol Oncol 2004; 93(2):320-7GO

Abstract

OBJECTIVE

Our objective is to examine how selenium (Se) supplementation influences oxidative stress (malondialdehyde) and the glutathione peroxidase system in patients with ovarian cancer undergoing chemotherapy.

MATERIAL

The study group included 31 patients with ovarian cancer undergoing chemotherapy receiving the drug Protecton Zellactiv (Smith Kline Beecham, Fink Naturarznei GmbH, Germany), two capsules, four times daily (200 microg).

RESULTS

Following the Se supplementation in a daily dose of 200 microg, the concentration of this microelement in serum (P < 0.05) and hair (P < 0.05) was significantly higher than in the control group. It has also been found that Se concentration in serum was significantly increased after 2 (P < 0.0000) and 3-months' (P < 0.0000) length of supplementation, as compared to the values after 1 month. In the hair of patients receiving this supplementation, an insignificantly higher concentration of this microelement was found after 2 (NS) and 3 months (NS) in comparison to the concentration after 1 month. The patients with ovarian cancer undergoing chemotherapy and receiving Se showed a significant increase in the activity of GSH-P(x) in erythrocytes after 2 months' (P < 0.0015) and 3 months' (P < 0.0038) supplementation. An increase of the concentration of malondialdehyde (MDA) following the administration of Se after 2 months (P < 0.0363) and 3 months (P < 0.0489) was found to be significant. The increase of MDA calculated into platelet count was found to be significant after 3 months (P 0.0477) of Se supplementation. Se administration for 3 months resulted in the significant increase of white blood cells (WBC) (P < 0.0001). After 2 and 3 months of Se administration, a significant decrease of hair loss (P < 0.0000; P < 0.0392, respectively), flatulence (P < 0.0000; P< 0.0000), abdominal pain (P < 0.0006; P < 0.0202), weakness (P < 0.0001; P < 0.0000), malaise (P < 0.0017; P < 0.0000), loss of appetite (P < 0.0000; P < 0.0000) was stated.

CONCLUSION

As a result of this clinical trial, we conclude that there are beneficial effects caused by ingesting selenium, as a supportive element in chemotherapy.

Authors+Show Affiliations

Department of Pharmacology, Pomeranian Academy of Medicine, Szczecin, Poland. ldoroz@uoo.univ.szczecin.pl

Pub Type(s)

Clinical Trial
Controlled Clinical Trial
Journal Article

Language

eng

PubMed ID

15099940

Citation

Sieja, Krzysztof, and Małgorzata Talerczyk. "Selenium as an Element in the Treatment of Ovarian Cancer in Women Receiving Chemotherapy." Gynecologic Oncology, vol. 93, no. 2, 2004, pp. 320-7.
Sieja K, Talerczyk M. Selenium as an element in the treatment of ovarian cancer in women receiving chemotherapy. Gynecol Oncol. 2004;93(2):320-7.
Sieja, K., & Talerczyk, M. (2004). Selenium as an element in the treatment of ovarian cancer in women receiving chemotherapy. Gynecologic Oncology, 93(2), pp. 320-7.
Sieja K, Talerczyk M. Selenium as an Element in the Treatment of Ovarian Cancer in Women Receiving Chemotherapy. Gynecol Oncol. 2004;93(2):320-7. PubMed PMID: 15099940.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Selenium as an element in the treatment of ovarian cancer in women receiving chemotherapy. AU - Sieja,Krzysztof, AU - Talerczyk,Małgorzata, PY - 2002/09/27/received PY - 2003/12/02/revised PY - 2003/12/16/accepted PY - 2004/4/22/pubmed PY - 2004/6/21/medline PY - 2004/4/22/entrez SP - 320 EP - 7 JF - Gynecologic oncology JO - Gynecol. Oncol. VL - 93 IS - 2 N2 - OBJECTIVE: Our objective is to examine how selenium (Se) supplementation influences oxidative stress (malondialdehyde) and the glutathione peroxidase system in patients with ovarian cancer undergoing chemotherapy. MATERIAL: The study group included 31 patients with ovarian cancer undergoing chemotherapy receiving the drug Protecton Zellactiv (Smith Kline Beecham, Fink Naturarznei GmbH, Germany), two capsules, four times daily (200 microg). RESULTS: Following the Se supplementation in a daily dose of 200 microg, the concentration of this microelement in serum (P < 0.05) and hair (P < 0.05) was significantly higher than in the control group. It has also been found that Se concentration in serum was significantly increased after 2 (P < 0.0000) and 3-months' (P < 0.0000) length of supplementation, as compared to the values after 1 month. In the hair of patients receiving this supplementation, an insignificantly higher concentration of this microelement was found after 2 (NS) and 3 months (NS) in comparison to the concentration after 1 month. The patients with ovarian cancer undergoing chemotherapy and receiving Se showed a significant increase in the activity of GSH-P(x) in erythrocytes after 2 months' (P < 0.0015) and 3 months' (P < 0.0038) supplementation. An increase of the concentration of malondialdehyde (MDA) following the administration of Se after 2 months (P < 0.0363) and 3 months (P < 0.0489) was found to be significant. The increase of MDA calculated into platelet count was found to be significant after 3 months (P 0.0477) of Se supplementation. Se administration for 3 months resulted in the significant increase of white blood cells (WBC) (P < 0.0001). After 2 and 3 months of Se administration, a significant decrease of hair loss (P < 0.0000; P < 0.0392, respectively), flatulence (P < 0.0000; P< 0.0000), abdominal pain (P < 0.0006; P < 0.0202), weakness (P < 0.0001; P < 0.0000), malaise (P < 0.0017; P < 0.0000), loss of appetite (P < 0.0000; P < 0.0000) was stated. CONCLUSION: As a result of this clinical trial, we conclude that there are beneficial effects caused by ingesting selenium, as a supportive element in chemotherapy. SN - 0090-8258 UR - https://www.unboundmedicine.com/medline/citation/15099940/Selenium_as_an_element_in_the_treatment_of_ovarian_cancer_in_women_receiving_chemotherapy_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0090825803008874 DB - PRIME DP - Unbound Medicine ER -